Geniposidic acid 

Geniposidic acid is an effective anticancer and radioprotection agent. Target: Others Mice were given an intraperitoneal injection of Geniposidic acid (GA) (12.5, 25, 50 mg/kg) 1 h before receiving GA against d-galactosamine (GalN) (800 mg/kg)/LPS (40 μg/kg). Liver and blood samples were collected 1 and 8 h after GalN/LPS injection. The survival rate of the GA group was significantly higher than the control. GalN/LPS increased serum aminotransferase activity, serum tumor necrosis factor-α level and hepatic lipid peroxidation and decreased hepatic glutathione content [1]. GA enhanced significantly the postirradiation responses of splenic blastogenesis by PHA. In addition, GA is a potent tumor growth inhibitor when combined with the X-irradiation, though there was no significant synergetic effect on their combined antitumor activity. The preliminary results of GA on hematological and blastogenic observations in this study suggested that it may very well, partially, play a role in an effective anticancer product with the ability to decrease undesirable radiation damage to the hematologic tissue after high dose irradiation [2].

374.34

Solid

C₁₆H₂₂O₁₀

27741-01-1

O[[email protected]]1[[email protected]](O)[[email protected]@H](CO)O[[email protected]@H](O[[email protected]@H]2OC=C(C(O)=O)[[email protected]]3([H])[[email protected]@]2([H])C(CO)=CC3)[[email protected]@H]1O

Room temperature in continental US; may vary elsewhere.

• [1]. Kim, S.J., et al., Geniposidic acid protects against D-galactosamine and lipopolysaccharide-induced hepatic failure in mice. J Ethnopharmacol, 2013. 146(1): p. 271-7.  [Content Brief]

  [2]. Hsu, H.Y., et al., Comparisons of geniposidic acid and geniposide on antitumor and radioprotection after sublethal irradiation. Cancer Lett, 1997. 113(1-2): p. 31-7.  [Content Brief]